Bristol-Myers Squibb (BMY) Insider Files Form 144 for 56,000 Shares
Rhea-AI Filing Summary
Bristol-Myers Squibb Co. (BMY) filed a Form 144 notifying the proposed sale of 56,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of $2,648,800.00. The filing reports total shares outstanding of 2,035,435,838 and an approximate sale date of 09/02/2025. The shares to be sold were acquired over 2021–2023 through stock option exercises and restricted stock vesting, with acquisition amounts listed by date (e.g., 2,976 on 08/12/2021; 19,326 on 09/13/2022). No securities were reported sold in the past three months.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Form 144 disclosing an insider sale of 56,000 shares (approximate value $2.65M) sourced from prior compensation and option exercises.
The filing documents a proposed sale through Fidelity on the NYSE with explicit acquisition history showing stock option exercises and restricted stock vesting across 2021–2023. The size of the sale relative to total outstanding shares (2,035,435,838) is small. There are no reported sales in the prior three months, and the filer affirms no undisclosed material adverse information. Impact appears procedural rather than company-changing.
TL;DR: Disclosure meets Rule 144 requirements and identifies compensation-related share sources, indicating compliance-focused reporting.
The schedule breaks down the origin of shares (option exercises and vesting) with dates and amounts, which supports transparency about the insider's basis and timing. The filing includes the standard representation regarding material nonpublic information and does not indicate reliance on a 10b5-1 plan in the remarks. This is a routine insider sale notice with limited material impact on governance or capitalization.